MX2009006871A - Compuestos heterociclicos con actividad antagonista de cxcr3. - Google Patents
Compuestos heterociclicos con actividad antagonista de cxcr3.Info
- Publication number
- MX2009006871A MX2009006871A MX2009006871A MX2009006871A MX2009006871A MX 2009006871 A MX2009006871 A MX 2009006871A MX 2009006871 A MX2009006871 A MX 2009006871A MX 2009006871 A MX2009006871 A MX 2009006871A MX 2009006871 A MX2009006871 A MX 2009006871A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- diseases
- formula
- limiting example
- non limiting
- Prior art date
Links
- 229940126692 CXCR3 antagonist Drugs 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000019872 Drug Eruptions Diseases 0.000 abstract 1
- 208000032678 Fixed drug eruption Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010027260 Meningitis viral Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- 208000012587 fixed pigmented erythema Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 238000009116 palliative therapy Methods 0.000 abstract 1
- 238000009117 preventive therapy Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 201000006382 tuberculoid leprosy Diseases 0.000 abstract 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 abstract 1
- 201000010044 viral meningitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Abstract
La presente solicitud revela un compuesto, o enantiómeros, estereoisómeros, rotámeros, tautómeros, racematos o profármacos de dicho compuesto, o sales, solvatos o ésteres aceptables para uso farmacéutico de dicho compuesto, o de dicho profármaco, teniendo dicho compuesto la estructura general que se muestra en la Fórmula 1 o Fórmula 5: (ver fórmulas (1) y (5)) o una sal, solvato o éster del mismo aceptable para uso farmacéutico. También se revela un método para tratar enfermedades mediadas por quimiocinas, tales como terapia paliativa, terapia curativa, terapia profiláctica de ciertas enfermedades y afecciones tales como enfermedades inflamatorias (los ejemplos no limitantes incluyen psoriasis), enfermedades autoinmunes (los ejemplos no limitantes incluyen artritis reumatoide, esclerosis múltiple), rechazo de injertos (los ejemplos no limitantes incluyen rechazo a aloinjerto, rechazo a xenoinjerto), enfermedades infecciosas (por ejemplo, lepra tuberculoide), erupciones fijas por fármacos, respuestas de hipersensibilidad cutánea de tipo retardado, inflamación oftálmica, diabetes tipo I, meningitis viral y tumores, utilizando un compuesto de Fórmula 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87147506P | 2006-12-22 | 2006-12-22 | |
| PCT/US2007/026039 WO2008079279A1 (en) | 2006-12-22 | 2007-12-20 | Heterocyclic compounds with cxcr3 antagonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006871A true MX2009006871A (es) | 2009-07-07 |
Family
ID=39315214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006871A MX2009006871A (es) | 2006-12-22 | 2007-12-20 | Compuestos heterociclicos con actividad antagonista de cxcr3. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120157466A1 (es) |
| EP (1) | EP2094688A1 (es) |
| JP (1) | JP2010513520A (es) |
| CN (1) | CN101583610A (es) |
| AR (1) | AR064609A1 (es) |
| CA (1) | CA2673231A1 (es) |
| MX (1) | MX2009006871A (es) |
| TW (1) | TW200845990A (es) |
| WO (1) | WO2008079279A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1858895B1 (en) | 2005-02-16 | 2012-06-20 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| AU2006214477A1 (en) | 2005-02-16 | 2006-08-24 | Pharmacopeia, Inc. | Heterocyclic substituted piperazines with CXCR3 antagonist activity |
| MX2007009949A (es) | 2005-02-16 | 2007-09-26 | Schering Corp | Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3. |
| EP1853587B1 (en) | 2005-02-16 | 2011-08-03 | Schering Corporation | Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity |
| AU2006214378A1 (en) | 2005-02-16 | 2006-08-24 | Pharmacopeia, Inc. | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity |
| CN101341147A (zh) | 2005-10-11 | 2009-01-07 | 先灵公司 | 具有cxcr3拮抗剂活性的取代的杂环化合物 |
| AR059962A1 (es) | 2006-03-21 | 2008-05-14 | Schering Corp | Compuestos de piridina sustituida con heterociclos con actividad antagonista de cxcr3 |
| CA2655372A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| CN101516869A (zh) | 2006-07-14 | 2009-08-26 | 先灵公司 | 具有cxcr3拮抗剂活性的杂环取代的哌嗪化合物 |
| JP5550352B2 (ja) | 2007-03-15 | 2014-07-16 | ノバルティス アーゲー | 有機化合物およびその使用 |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| GB201017345D0 (en) * | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| WO2013060865A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| JP6073931B2 (ja) | 2012-02-02 | 2017-02-01 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ４−（ベンゾイミダゾール−２−イル）−チアゾール化合物及び関連するアザ誘導体 |
| EP3024832B1 (en) | 2013-07-22 | 2018-03-28 | Idorsia Pharmaceuticals Ltd | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| AR099789A1 (es) | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| MA41337A (fr) | 2015-01-15 | 2017-11-22 | Idorsia Pharmaceuticals Ltd | Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3 |
| JP6927882B2 (ja) | 2015-04-02 | 2021-09-01 | プロキシマジェン，リミティド ライアビリティ カンパニー | 癌の新治療法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074801B1 (en) * | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| WO2003082855A1 (en) * | 2002-03-28 | 2003-10-09 | Kyowa Hakko Kogyo Co., Ltd. | Anti-inflammatory agent |
| US7635698B2 (en) * | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| MX2007009949A (es) * | 2005-02-16 | 2007-09-26 | Schering Corp | Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3. |
| AU2006214378A1 (en) * | 2005-02-16 | 2006-08-24 | Pharmacopeia, Inc. | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity |
| US7566718B2 (en) * | 2005-02-16 | 2009-07-28 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity |
| EP1858895B1 (en) * | 2005-02-16 | 2012-06-20 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| PE20061164A1 (es) * | 2005-02-16 | 2006-10-27 | Schering Corp | Piperazin-piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3 |
-
2007
- 2007-12-20 WO PCT/US2007/026039 patent/WO2008079279A1/en not_active Ceased
- 2007-12-20 CA CA002673231A patent/CA2673231A1/en not_active Abandoned
- 2007-12-20 MX MX2009006871A patent/MX2009006871A/es not_active Application Discontinuation
- 2007-12-20 AR ARP070105774A patent/AR064609A1/es not_active Application Discontinuation
- 2007-12-20 CN CNA2007800500424A patent/CN101583610A/zh active Pending
- 2007-12-20 JP JP2009542918A patent/JP2010513520A/ja active Pending
- 2007-12-20 US US12/519,970 patent/US20120157466A1/en not_active Abandoned
- 2007-12-20 EP EP07863159A patent/EP2094688A1/en not_active Withdrawn
- 2007-12-21 TW TW096149571A patent/TW200845990A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010513520A (ja) | 2010-04-30 |
| EP2094688A1 (en) | 2009-09-02 |
| CN101583610A (zh) | 2009-11-18 |
| WO2008079279A1 (en) | 2008-07-03 |
| CA2673231A1 (en) | 2008-07-03 |
| US20120157466A1 (en) | 2012-06-21 |
| TW200845990A (en) | 2008-12-01 |
| AR064609A1 (es) | 2009-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006871A (es) | Compuestos heterociclicos con actividad antagonista de cxcr3. | |
| MX2008012161A (es) | Compuestos heterociclicos de piridina sustituida con actividad antagonista de cxcr3. | |
| WO2006088837A3 (en) | Heterocyclic substituted piperazines with cxcr3 antagonist activity | |
| IL185188A0 (en) | Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity | |
| WO2006088836A3 (en) | Piperazine-piperidines with cxcr3 antagonist activity | |
| WO2006088919A3 (en) | Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity | |
| TW200640902A (en) | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | |
| TW200640906A (en) | Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity | |
| WO2006088921A3 (en) | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity | |
| ATE546445T1 (de) | Substituierte heterocyclische verbindungen mit cxcr3-antagonistischer wirkung | |
| TNSN05252A1 (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders : process for their preparation and pharmaceutical compositions containing them | |
| LUC00155I2 (es) | ||
| WO2005051906A3 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| WO2006124490A3 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| CZ20011394A3 (cs) | Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje | |
| ATE388952T1 (de) | Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel | |
| AU2003263393A1 (en) | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | |
| NO20051100L (no) | Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer | |
| MA26769A1 (fr) | Derives de thioamide. | |
| WO2011124525A1 (de) | Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten | |
| MX2008009413A (es) | Heterociclos como agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia. | |
| EP2555773A1 (de) | Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten | |
| RU2007135053A (ru) | Замещенные производные пиридо(2, 3-d)пиримидина, пригодные в качестве лекарственных средств для лечения аутоиммунных нарушений | |
| ES2087038A1 (es) | Nuevas piperidinas con actividad antagonista del paf. | |
| JO2527B1 (en) | Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |